MORAGA, Calif., Sept. 25, 2013 (GLOBE NEWSWIRE) -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, will be presenting clinical data for its leading drug candidate, TI-001, intranasal oxytocin, for the treatment of chronic migraine at the 7th Annual Pain Therapeutics Summit East, hosted by Arrowhead Publishers, September 25th-26th, 2013, in Boston, Massachusetts.
Help employers find you! Check out all the jobs and post your resume.
